Today I added a starter position in CDTX. Data should be coming out there in the last week of March, per the company. This company is run by Jeffrey Stein, who was the former CEO of Trius Therapeutics, which got bought out a few years ago. Point being, I like the management team there and think we get a nice little run up over the next week and a half.
The market has been extremely choppy. Even throughout the day we’ll go up 100, then down 100, then end the day flat – just as an example.
Cohn resigned today and that has caused a big market drop in the futures.
I’ve been really cautious and slow because of these conditions – as I’ve stated day after day in this watch list.
Let’s continue to practice that discipline and continue to look for good opportunities.
Just a reminder, charts and targets are updated every Monday morning!
Catalyst Swing names (1 – 4 week holds) I am watching…
TherapeuticsMD (TXMD)
Catalyst Dates: FDA approval date of May 29th
Buy Zone: $4.90 to $5.20
Profit Zone: $6.00 or higher
Stop Zone: $4.60 or below
Edge Therapeutics (EDGE)
Catalyst Dates: Phase 3 interim data due out in April
Buy Zone: $15.20 to $15.50
Profit Zone: $16.50 or higher
Stop Zone: $15.00 or below
Medicinova (MNOV)
Catalyst Dates: Phase 1b/2a abstract to be presented April 27th
Buy Zone: $10.50 to $11.00
Profit Zone: $12.00 or higher
Stop Zone: $10.15 or below
Catalyst Swing names (1 – 4 week holds) I am watching…
Selecta Biosciences (SELB)
Catalyst Dates: Phase 2 data in early April
Buy Zone: $8.50 to $9.50
Profit Zone: $11.50 or higher
Stop Zone: $8.00 or below
Viking Therapeutics (VKTX)
Catalyst Dates: Phase 2 data for fatty liver disease due out in the 2nd quarter.
Buy Zone: $6.00 to $6.50
Profit Zone: $7.50 or higher
Stop Zone: $5.50 or below
Seattle Genetics (SGEN)
Catalyst Dates: FDA approval date of May 1
Buy Zone: $53.00 to $56.00
Profit Zone: $60.00 or higher
Stop Zone: $51.50 or below
Dova Pharmaceuticals (DOVA)
Catalyst Dates: FDA approval date of May 21
Buy Zone: $30.00 to $32.00
Profit Zone: $36.00 or higher
Stop Zone: $29.50 or below
Rigel Pharmaceuticals (RIGL)
Catalyst Dates: FDA approval date of April 17th for immune thrombocytopenic purpura
Buy Zone: $3.50 to $3.90
Profit Zone: $4.50 or higher
Stop Zone: $3.40 or below
Clovis Oncology (CLVS)
Catalyst Dates: FDA approval date of April 6th for ovarian cancer
Buy Zone: $52.00 to $55.00
Profit Zone: $60.00 or higher
Stop Zone: $49.00 or below
Savara (SVRA)
Catalyst Dates: Phase 2 heart failure data due on March 11th
Buy Zone: $11.75 to $12.50
Profit Zone: $14.00 or higher
Stop Zone: $11.00 or below
Ultragenyx Pharmaceuticals (RARE)
Catalyst Dates: FDA approval date of April 17th for X-linked Hypophosphatemia
Buy Zone: $44.00 to $47.00
Profit Zone: $55.00 or higher
Stop Zone: $41.00 or below
Progenics (PGNX)
Catalyst Dates: FDA Approval date of April 30th
Buy Zone: $5.75 to $6.20
Profit Zone: $7.00 or higher
Stop Zone: $5.10 or below
CorMedix (CRMD)
Catalyst Dates: Phase 3 interim analysis due out in the second quarter. Likely a buy after their earnings call in March.
Buy Zone: $.30 to $.40
Profit Zone: $.60 or higher
Stop Zone: $.25 or below
EDAP Tms (EDAP)
Catalyst Dates: FDA medical device approval for prostate cancer likely late 1Q
Buy Zone: $2.40 to $2.70
Profit Zone: $3.40 or higher
Stop Zone: $2.20 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.50 to $6.00
Profit Zone: $8.00 or higher
Stop Zone: $5.20 or below
Cidara Therapeutics (CDTX)
Catalyst Dates: Phase 2 Candidemia data due in the 1Q (likely sometime in March)
Buy Zone: $6.50 to $7.00
Profit Zone: $8.00 or higher
Stop Zone: $5.75 or below
Sophiris Bio (SPHS)
Catalyst Dates: Phase 2b initial biopsy data due late First Quarter.
Buy Zone: $1.95 to $2.15
Profit Zone: $2.40 or higher
Stop Zone: $1.75 or below
[Ed. Note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.